2Seventy Bio Inc expected to post a loss of 26 cents a share - Earnings Preview

2Seventy Bio

14/03/2025 12:36

2Seventy Bio Inc TSVT.OQ TSVT.O is expected to show a rise in quarterly revenue when it reports  results on March 17 (estimated) for the period ending December 31 2024

The Cambridge Massachusetts-based  company is expected to report a 8.6% increase in revenue to $11.599 million from $10.68 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for 2Seventy Bio Inc is for a loss of 26 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for 2Seventy Bio Inc is $5.00​, above​ its last closing price of $4.95. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.23
-0.24
-0.19
Beat
21.2
Jun. 30 2024
-0.76
-0.65
0.45
Beat
169.5
Mar. 31 2024
-0.79
-0.81
-1.01
Missed
-24.4​
Dec. 31 2023
-1.05
-0.99
-1.11
Missed
-12.1
​​Sep. 30 2023
-1.20
-1.03
-1.00
Beat
2.8
Jun. 30 2023
-1.09
-1.06
-0.83
Beat
22.1​
Mar. 31 2023
-1.20
-1.19
-1.08
Beat
9.5
Dec. 31 2022
-1.59
-1.61
-0.60
Beat
62.6

This summary was machine generated March 14 at 12:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)